echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Amino Acids Research > Announcement of Meihua Bio on the Pledge of Part equity of controlling Shareholders

    Announcement of Meihua Bio on the Pledge of Part equity of controlling Shareholders

    • Last Update: 2020-06-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 27,, MrMeng Qingshan, the controlling shareholder of Meihua Biotech Group Co., Ltd(hereinafter referred to as the Company or Meihua Bio), informed that MrMeng Qingshan had conducted a share pledge repurchase transaction at Huatron Securities Co., Ltd("Huatron Securities") on January 25, 2016 due to personal financing needsiGzMrMeng Qingshan will hold 51 million shares of unlimited tradable shares for stock pledge-type repurchase with Huatron Securities on January 25, 2016 and the repurchase date on January 25, 2017As of the date of this announcement, MrMeng Qingshan holds 854,103,033 shares of Meihua Bio, accounting for 27.48% of the total number of shares of the Company (the total share capital of the Company 3,108,226,603 shares), and the number of shares pledged in this pledge-type repurchase transaction accounts for 5.97% of the shares held by Meihua BioiGzAs of the date of this announcement, MrMeng Qingshan has pledged 319,240,000 shares, accounting for 37.38% of his shares held by Meihua Bio, accounting for 10.27% of the company's total share capitaliGzMrMeng Qingshan because of personal financing needs to pledge stocks, his personal credit is in good condition, with the corresponding ability to repay funds, the resulting pledge risk is under control iGz
      On January 27, Mr Meng Qingshan, the controlling shareholder of Meihua Biotech Group Co., Ltd (hereinafter referred to as the Company or Meihua Bio), informed that Mr Meng Qingshan had conducted a share pledge repurchase transaction on January 25, 2016 at Huatron Securities Co., Ltd ("Huatron Securities") due to personal financing needs iGz   Mr Meng Qingshan will hold 51 million shares of unlimited tradable shares for stock pledge-type repurchase with Huatron Securities on January 25, 2016 and the repurchase date on January 25, 2017 As of the date of this announcement, Mr Meng Qingshan holds 854,103,033 shares of Meihua Bio, accounting for 27.48% of the total number of shares of the Company (the total share capital of the Company 3,108,226,603 shares), and the number of shares pledged in this pledge-type repurchase transaction accounts for 5.97% of the shares held by Meihua Bio iGz   As of the date of this announcement, Mr Meng Qingshan has pledged 319,240,000 shares, accounting for 37.38% of his shares held by Meihua Bio, accounting for 10.27% of the company's total share capital iGz   Mr Meng Qingshan because of personal financing needs to pledge stocks, his personal credit is in good condition, with the corresponding ability to repay funds, the resulting pledge risk is under control iGz Share it on feed
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.